| DNLI Market Cap History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the DNLI market cap history going back to 12/8/2017:
Also see: DNLI Shares Outstanding History and DNLI YTD Return |
DNLI Market Cap History — Denali Therapeutics Capitalization Over Time
As of 7/31/2026 Denali Therapeutics has a market cap of 3.68 billion. Investors often follow the DNLI market cap history to compare the size of the company over time.
This page shows DNLI market capitalization trends over time, with 36 market cap datapoints presented, dating back to 12/8/2017.
| DNLI Market Cap History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DNLI Historical Market Cap: +8.85% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| DNLI Stock Price Chart |
| About Denali Therapeutics Inc |
| Denali Therapeutics Inc. is a biopharmaceutical company. Co. is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. Co. has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson's disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). We show 36 historical shares outstanding datapoints in our DNLI shares outstanding history coverage, used to compute DNLI market cap on those dates. Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing DNLI market cap history over the course of time is important for investors interested in comparing DNLI's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of DNLI versus a peer is one thing; comparing DNLI market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like DNLI can fluctuate over the course of history. With this page we aim to empower investors researching DNLI by allowing them to research the DNLI market cap history. |
| DNLI Current Stock Quote |
Quotes delayed 20 minutes  Free DNLI Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: The Importance of Market Cap | |
|
Video: The Importance of Market Cap
| DNLI Share Performance |
| Market Cap Peers |
| Denali Therapeutics (DNLI) is categorized under the Healthcare sector; to help you further research historical market cap numbers, below are some other companies in the same sector:
DNTH Market Cap History DOMH Market Cap History DOVA Market Cap History DPLO Market Cap History DRAD Market Cap History DRIO Market Cap History DRMA Market Cap History DRNA Market Cap History DRRX Market Cap History DSGN Market Cap History More Healthcare companies » |
DNLI Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
